Valuation: Lupin Limited

Market Cap 895B 9.48B 8.45B 7.82B 7.08B 13.34B 13.5B 93.8B 36.8B 470B 35.57B 34.83B 1,499B P/E 2027 *
20.3x
P/E 2028 * 19.1x
Enterprise Value 854B 9.05B 8.06B 7.47B 6.76B 12.73B 12.88B 89.52B 35.13B 449B 33.95B 33.24B 1,430B EV / Sales 2027 *
2.82x
EV / Sales 2028 * 2.54x
Free-Float
52.98%
Yield 2027 *
0.65%
Yield 2028 * 0.66%
1 day-2.05%
1 week-2.16%
Current month-6.13%
1 month-9.59%
3 months-20.32%
6 months-16.93%
Current year-9.24%
1 week 1,897.25
Extreme 1897.25
1,988.75
1 month 1,897.25
Extreme 1897.25
2,127
Current year 1,897.25
Extreme 1897.25
2,530
1 year 1,897.25
Extreme 1897.25
2,530
3 years 1,113
Extreme 1113
2,530
5 years 583.05
Extreme 583.05
2,530
10 years 505
Extreme 505
2,530
Manager TitleAgeSince
Chief Executive Officer 58 2013-08-31
Director of Finance/CFO 61 2007-08-12
Compliance Officer - 2024-08-31
Director TitleAgeSince
Director/Board Member 52 2008-10-07
Director/Board Member 58 1996-12-31
Chairman 83 2017-08-10
Change 5-day change 1-year change 3-year change Capi.($)
-2.05%-2.16%-1.20%+64.32% 9.48B
-1.01%+5.13%+58.93%+117.36% 1,133B
-0.61%+1.52%+34.34%+68.48% 621B
-1.48%+0.47%+23.08%+94.76% 503B
-0.56%+2.53%+38.79%+63.88% 379B
+1.07%+1.70%+71.06%+45.98% 370B
+0.49%+1.21%+21.51%+50.79% 292B
-0.22%-0.80%+0.45%+24.71% 262B
-0.14%+2.87%+45.56%+57.22% 237B
-1.88%+0.02%+23.77%+97.39% 190B
Average -0.35%+2.91%+31.63%+68.49% 399.75B
Weighted average by Cap. +0.22%+3.73%+40.63%+79.66%

Financials

2027 *2028 *
Net sales 303B 3.21B 2.86B 2.64B 2.39B 4.51B 4.56B 31.71B 12.44B 159B 12.03B 11.78B 507B 323B 3.42B 3.05B 2.82B 2.55B 4.81B 4.87B 33.81B 13.27B 170B 12.82B 12.56B 540B
Net income 44B 466M 416M 385M 348M 656M 664M 4.61B 1.81B 23.13B 1.75B 1.71B 73.7B 46.85B 496M 442M 410M 371M 698M 707M 4.91B 1.93B 24.63B 1.86B 1.82B 78.47B
Net Debt -40.8B -432M -385M -357M -323M -608M -615M -4.28B -1.68B -21.45B -1.62B -1.59B -68.34B -75.05B -795M -709M -656M -594M -1.12B -1.13B -7.87B -3.09B -39.45B -2.98B -2.92B -126B
Projected Income Statement - Annual - Lupin Limited
Logo Lupin Limited
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas: - design and production of generic and brand-name formulations; - production of active pharmaceutical ingredients. At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil. Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
Employees
26,021
Date Price Change Volume
26-10-22 ₹1,916.60 -2.06% 9,659
26-10-21 ₹1,957.00 +0.17% 42,945
26-10-19 ₹1,953.75 -0.10% 5,864
26-10-16 ₹1,955.80 -0.17% 30,595
26-10-15 ₹1,959.20 +0.23% 35,937
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Lupin Limited
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
36
Last Close Price
1,957.00INR
Average target price
2,446.14INR
Spread / Average Target
+24.99%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Lupin Limited
  1. Stock Market
  2. Stocks
  3. LUPIN Stock